Natural Human Interferon (Alpha-n3) is Active Against Both Wild-Type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus
September 12, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that at the 53rd annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy...
Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
September 12, 2013 07:45 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Chairman and CEO, William A. Carter, M.D. of Hemispherx Biopharma (NYSE MKT:HEB) announced at the Rodman and Renshaw Conference in New York City, NY on...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
September 12, 2013 07:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced that at the Options for the Control of Influenza VIII Conference in Cape Town, South Africa held...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Potentially Reduce Pandemic Influenza Spread
September 04, 2013 08:24 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT: HEB) announced that one of its advanced stage biological products, Alferon N Injection®, will be featured as...
Hemispherx Biopharma to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
September 03, 2013 16:05 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
August 26, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread
August 20, 2013 11:21 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
August 09, 2013 16:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...
Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's Audit Committee
July 29, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 29, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that effective July 23, 2013, the Board of Directors of Hemispherx...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2013
May 08, 2013 15:53 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 8, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2013. The net loss (including non-cash effects)...